<DOC>
	<DOCNO>NCT01900106</DOCNO>
	<brief_summary>1 . PROTOCOL SUMMARY This prospective , randomized open-label , 2 arm , 3-phase trial compare 48-weeks virological response two different regimen contain abacavir/lamivudine ( abacavir/lamivudine +darunavir/ritonavir ( DRV/r ) v abacavir/lamivudine + raltegravir ( RAL ) antiretroviral therapy naive , HIV+ individual present care CD4+ count &lt; 200/mm3 . 1.1 Clinical Objectives : Primary Objective : To compare 48-week virological response two different regimen contain abacavir/lamivudine ( abacavir/lamivudine +darunavir/ritonavir ( DRV/r ) v abacavir/lamivudine + raltegravir ( RAL ) antiretroviral therapy naive , HIV+ individual present care CD4+ count &lt; 200/mm3 . Secondary Objective : ) To compare immunological response 48 week ; b ) To determine safety tolerability 2 regimen . 1.2 Study population : 350 in/out patient 1.3 Outcome Primary Endpoint - Proportion patient HIV RNA &lt; 50 copies/mL 48 week Secondary Endpoints ( ) - Change CD4+ cell count baseline week 48 - Time virological rebound 1.4 Study design : Multicentre , parallel group , randomise , open label , non-inferiority study 1.5 Treatment regimen : Arm A : abacavir/lamivudine 1 tablet day + raltegravir 400 mg ( 1 tablet twice day ) Arm B : abacavir/lamivudine 1 tablet day + ritonavir 100 mg + darunavir 800 mg day . All drug approve treatment HIV infection . The study population consist 350 HIV-positive , HLA B5701-negative patient . At baseline , patient randomize 1:1 start abacavir/lamivudine plus either raltegravir darunavir/ritonavir . Randomization stratify basis screen CD4+ cell count ( ≤100 v ≥100 cells/µL ) , ensure balance across treatment group 1.7 Criteria Safety : Adverse event laboratory assessment . 1.8 Statistical analysis : As non-inferiority trial , calculate difference proportion patient experience primary outcome two treatment arm calculate 95 % confidence interval . Non-inferiority raltegravir arm demonstrate low limit 95 % confidence interval great -12 % . In case non-inferiority meet , analyse superiority perform .</brief_summary>
	<brief_title>A Prospective , Open-label Trial Two ABC/3TC Based Regimens Late Presenter naïve Patients ( CD4 &lt; 200 Cells/µL )</brief_title>
	<detailed_description>1 . PROTOCOL SUMMARY This prospective , randomized open-label , 2 arm , 3-phase trial compare 48-weeks virological response two different regimen contain abacavir/lamivudine ( abacavir/lamivudine +darunavir/ritonavir ( DRV/r ) v abacavir/lamivudine + raltegravir ( RAL ) antiretroviral therapy naive , HIV+ individual present care CD4+ count &lt; 200/mm3 . 1.1 Clinical Objectives : Primary Objective : To compare 48-week virological response two different regimen contain abacavir/lamivudine ( abacavir/lamivudine +darunavir/ritonavir ( DRV/r ) v abacavir/lamivudine + raltegravir ( RAL ) antiretroviral therapy naive , HIV+ individual present care CD4+ count &lt; 200/mm3 . Secondary Objective : 1 . To compare immunological response 48 week ; 2 . To determine safety tolerability 2 regimen . 1.2 Study population : 350 inpatient outpatient randomize 1.3 Outcome Primary Endpoint - Proportion patient undetectable viremia ( HIV RNA &lt; 50 copies/mL ) 48 week Secondary Endpoints ( ) - Change CD4+ cell count baseline week 48 - Time virological rebound Safety endpoints - Incidence adverse event ( AEs ) - Incidence serious adverse event ( SAEs ) - Discontinuations due adverse event - Incidence grade 3 4 laboratory abnormality . 1.4 Study design Multicentre , parallel group , randomise , open label , non-inferiority study 1.5 Planned sample size : The planned sample size trial 350 patient 1.6 Treatment regimen : Arm A : abacavir/lamivudine 1 tablet day + raltegravir 400 mg ( 1 tablet twice day ) Arm B : abacavir/lamivudine 1 tablet day + ritonavir 100 mg + darunavir 800 mg day . All drug approve treatment HIV infection . Administration : oral The study population consist 350 HIV-positive , HLA B5701-negative patient . At baseline , patient randomize 1:1 start abacavir/lamivudine plus either raltegravir darunavir/ritonavir . Randomization stratify basis screen CD4+ cell count ( ≤100 v ≥100 cells/µL ) , ensure balance across treatment group 1.7 Criteria Safety : Adverse event laboratory assessment . 1.8 Statistical analysis : As non-inferiority trial , calculate difference proportion patient experience primary outcome two treatment arm calculate 95 % confidence interval . Non-inferiority raltegravir arm demonstrate low limit 95 % confidence interval great -12 % . In case non-inferiority meet , analyse superiority perform .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>1 . Males female ( inpatient outpatient ) age 1864 year HIV1 antibody seropositive , CD4 count &lt; 200 cells/uL . 2 . All patient antiretroviralnaive 3 . All patient HLA B57 HLA B5701 negative 4 . Patients must HIV RNA level &lt; 500,000 copies/mL 5 . Patients active opportunistic infection could enrol long diagnosed 2 week prior screen . 6 . Patients must meet follow laboratory criterion . Neutrophil count &gt; 1,000 cells/mm3 Haemoglobin &gt; 9.0 grams/dl ( men woman ) Platelet count ≥ 75,000 cells/mm3 Alkaline phosphatase &lt; 3.0 upper limit normal ALT AST &lt; 3.9 time upper limit normal Total bilirubin &lt; 1.5 time upper limit normal . 7 . Female patient childbearing potential must willing use reliable form contraception , include medically approve form barrier contraception . 8 . Patients must able provide write consent comply study requirement . 1 . Patients genotypic mutation study drug . 2 . Patients opportunistic infection diagnose 2 week prior screen . 3 . Female patient pregnant breastfeeding . 4 . Patients receive investigational drug antineoplastic radiotherapy/chemotherapy local skin radiotherapy within 12 week randomization . 5 . Patients current history intravenous drug abuse , alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>late presenter</keyword>
	<keyword>naïve</keyword>
	<keyword>advanced HIV disease</keyword>
</DOC>